Top

Published in:

01-10-2007 | Breast Oncology

Molecular Breast Cancer Subtypes in Premenopausal African-American Women, Tumor Biologic Factors and Clinical Outcome

Authors: Chukwuemeka U. Ihemelandu, LaSalle D. Leffall Jr., Robert L. Dewitty, Tammey J. Naab, Haile M. Mezghebe, Kepher H. Makambi, Lucile Adams-Campbell, Wayne A. Frederick

Published in: Annals of Surgical Oncology | Issue 10/2007

Abstract

Introduction

Breast cancer is currently viewed as a heterogeneous disease made up of various subtypes, with distinct differences in prognosis. Our goal was to study the distribution and to characterize the clinical and biological factors that influence the behavior and clinical management of the different molecular breast cancer subtypes in premenopausal African-American women.

Methods

A retrospective analysis of Howard University Hospital tumor registry, for all premenopausal African-American women aged less than 50 years, diagnosed with breast cancer from 1998–2005, was performed.

Results

The luminal A subtype was the most prevalent (50.0%), vs basal-cell-like (23.2%), luminal B (14.1%), and HER-2/neu (12.7%). However when stratified by age groups, results showed that in the age group <35 years the basal-cell-like subtype was the most prevalent (55.6%), vs 25.9%, 14.8%, and 5.6% for luminal A, luminal B, and HER-2/neu subtypes, respectively (P < .000). P53 mutation was more prevalent in the basal-cell-like subtype compared to luminal A (48.0% vs 18.6%, P < .01).

The expression of the Bcl-2 gene differed by subtype, with the luminal A and luminal B subtypes more likely to overexpress the Bcl-2 gene (89.1% luminal A, 80.0% luminal B vs 47.6% basal-cell-like and 40.0% HER-2/neu, P < .000). Though not statistically significant, HER-2/neu and basal-cell-like subtypes had the shortest survival time (P < .31).

Conclusion

The high prevalence of the basal-cell-like subtype in young premenopausal African-American women aged <35 years may contribute to the poorer prognosis observed in this cohort of African-American women.

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 13 Regs Public-Use, Nov 2005 Sub (1992–2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the Nov 2005 submission

Swanson GM, Haslam SZ, Azzouz F. Breast cancer among young African-American women. Cancer 2003; 97(1 suppl):273–79CrossRef

Clarke CA, West DW, Edwards BK, Figgs LW, Kerner J, Schwartz AG. Existing data on breast cancer in African-American women: what we know and what we need to know. Cancer 2003; 97(1 suppl):211–21PubMedCrossRef

Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975–2002. Bethesda, MD: National Cancer Institute; 2005

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality—All COD, Public-Use With State, Total U.S. for Expanded Races/Hispanics (1990–2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006. Underlying mortality data provided by NCHS (www.cdc.gov/nchs)

Bain RP, Greenberg RS, Whitaker JP. Racial differences in survival of women with breast cancer. J Chronic Dis 1986; 39:631–42PubMedCrossRef

Dayal HH, Power RN, Chiu C. Race and socio-economic status in survival from breast cancer. J Chronic Dis 1982; 35:675–83PubMedCrossRef

Bassett MT, Krieger N. Social class and black-white differences in breast cancer. Am J Public Health 1986; 76:1400–3PubMedCrossRef

Vastag B. Breast cancer racial gap examined: no easy answers to explain disparities in survival. JAMA 2003; 290:1838–42PubMedCrossRef

10.

Eley JW, Hill HA, Chen VW, et al. Racial differences in survival from breast cancer: results of the National Cancer Institute Black/White Cancer Survival Study. JAMA 1994; 272:947–54PubMedCrossRef

11.

Elledge RM, Clark GM, Chamness GC, et al. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 1994; 86:705–12PubMedCrossRef

12.

Polite BN, Olopade OI. Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med 2005; 48(1 Suppl):S166–S175PubMed

13.

Furberg H, Millikan R, Dressler L, Newman B, Geradts J. Tumor characteristics in African American and white women. Breast Cancer Res Treat 2001; 68:33–43PubMedCrossRef

14.

Porter PL, Lund MJ, Lin MG, et al. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 2004; 100:2533–42PubMedCrossRef

15.

Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747–52PubMedCrossRef

16.

Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869–74PubMedCrossRef

17.

Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100:8418–23PubMedCrossRef

18.

Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10:5367–74PubMedCrossRef

19.

Carey LA, Perou CM, Livasy CA, et al. Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. JAMA 2006; 295:2492–2502PubMedCrossRef

20.

Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer, college of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124:966–78PubMed

21.

Carey LA, Dees EC, Sawyer LR, et al. The triple negative paradox: Primary tumor chemosensitivity of Breast Cancer Subtypes. Clin Cancer Res 2007; 13(8):2329–34PubMedCrossRef

22.

Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 2:264–71CrossRef

23.

Thor AD, Moore DM, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84:845–55PubMedCrossRef

24.

Davidoff AM, Humphrey PA, Iglehart JD, Marks JR. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 1991; 88:5006–10PubMedCrossRef

25.

Banks L, Matlashewski G, Crawford L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986; 159:529–34PubMedCrossRef

26.

Bartek J, Bartkova J, Vojtesek B, et al. Patterns of expression of p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer 1990; 46:839–44PubMedCrossRef

27.

Histological Typing of Breast Tumours, 2nd ed. World Health Organization, Geneva, Switzerland, 1981). International Classification of Tumours

28.

Fitzgibbons PL, Connolly JL, Page DL. Updated protocol for the examination of specimens from patients with carcinomas of the breast, a basis for checklists. Arch Pathol Lab Med 2000; 124:1026–33PubMed

29.

Rolland P, Spendlove I, Madjid Z, Rakha EA, Patel P, Ellis IO, Durrant L. The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. Int J Cancer 2007; 120:1311–7PubMedCrossRef

30.

Horita K, Yamaguchi A, Hirose K, Ishida M, Noriki S, Imamura Y, Fukuda M. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer. Eur J Histochem 2001; 45:73–84PubMed

31.

Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 1996; 14:1604–10PubMed

32.

Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347(16):1233–41PubMedCrossRef

33.

Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347(16):1227–32PubMedCrossRef

34.

Haffty BG, Yang Q, Reiss M, et al. Locoregional and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24:5652–7PubMedCrossRef

35.

Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Eng J Med 2005; 353:1673–84CrossRef

36.

Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24:1037–44PubMedCrossRef

37.

Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23:7212–20PubMedCrossRef

38.

Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11:5678–85PubMedCrossRef

Title: Molecular Breast Cancer Subtypes in Premenopausal African-American Women, Tumor Biologic Factors and Clinical Outcome
Authors: Chukwuemeka U. Ihemelandu
LaSalle D. Leffall Jr.
Robert L. Dewitty
Tammey J. Naab
Haile M. Mezghebe
Kepher H. Makambi
Lucile Adams-Campbell
Wayne A. Frederick
Publication date: 01-10-2007
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 10/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9477-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Molecular Breast Cancer Subtypes in Premenopausal African-American Women, Tumor Biologic Factors and Clinical Outcome

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2007

Sentinel Lymph Node Biopsy Performed After Neoadjuvant Chemotherapy is Accurate in Patients with Documented Node-Positive Breast Cancer at Presentation

Prognostic Significance of VEGF Expression in Correlation With COX-2, Microvessel Density, and Clinicopathological Characteristics in Human Gastric Carcinoma

Biliary Obstruction in Gall Bladder Cancer Is Not Sine Qua Non of Inoperability

Isolated Tumor Cells in the Sentinel Node Affect Long-Term Prognosis of Patients with Melanoma

The UK NCRI MAGIC Trial of Perioperative Chemotherapy in Resectable Gastric Cancer: Implications for Clinical Practice

Outcomes for Women With Ductal Carcinoma-in-Situ and a Positive Sentinel Node: A Multi-Institutional Audit